tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Cognition Therapeutics regains compliance with Nasdaq
PremiumThe FlyCognition Therapeutics regains compliance with Nasdaq
1M ago
Cognition Therapeutics Reports Q2 2025 Financial Results
Premium
Company Announcements
Cognition Therapeutics Reports Q2 2025 Financial Results
1M ago
Cognition Therapeutics confirms aligment with FDA on path for zervimesine
Premium
The Fly
Cognition Therapeutics confirms aligment with FDA on path for zervimesine
2M ago
Cognition Therapeutics publishes results of analysis from Phase 2 SEQUEL study
PremiumThe FlyCognition Therapeutics publishes results of analysis from Phase 2 SEQUEL study
2M ago
Cognition Therapeutics ot present data from zervimesine Phase 2 study
Premium
The Fly
Cognition Therapeutics ot present data from zervimesine Phase 2 study
2M ago
Cognition Therapeutics Receives Buy Rating Amid Promising Developments and Regulatory Advancements for Zervimesine
Premium
Ratings
Cognition Therapeutics Receives Buy Rating Amid Promising Developments and Regulatory Advancements for Zervimesine
3M ago
Cognition to conduct end-of-Phase 2 meeting with FDA on zervimesine
PremiumThe FlyCognition to conduct end-of-Phase 2 meeting with FDA on zervimesine
3M ago
Cognition Therapeutics Holds Virtual Annual Stockholders Meeting
Premium
Company Announcements
Cognition Therapeutics Holds Virtual Annual Stockholders Meeting
3M ago
Cognition Therapeutics: Buy Rating Affirmed on Non-Dilutive Funding and Regulatory Progress for Zervimesine
Premium
Ratings
Cognition Therapeutics: Buy Rating Affirmed on Non-Dilutive Funding and Regulatory Progress for Zervimesine
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100